PMID- 31894029
OWN - NLM
STAT- MEDLINE
DCOM- 20200701
LR  - 20200701
IS  - 1011-601X (Print)
IS  - 1011-601X (Linking)
VI  - 32
IP  - 5(Special)
DP  - 2019 Sep
TI  - Efficacy and safety of NAD+ ADP-ribosyltransferase 1 agonist versus Donepezil in 
      elderly Chinese patients with Alzheimer disease: A novel target for effective 
      therapy.
PG  - 2427-2432
AB  - This pilot study designed to evaluate the efficacy and safety of NAD+ ADP-ribosyl 
      transferase 1 (NART) agonist in comparison with Donepezil (DNP) in elderly 
      Chinese patients with Alzheimer disease (AD). In the present clinical trial, 
      Chinese elderly patients aged >65 years with a confirmed diagnosis of AD were 
      enrolled. The patients received NART agonist (test, DAG-structured PKC blockers 
      (GF109203X)) or DNP 10mg daily (reference) for 6 months. The efficacy and safety 
      data were collected from 120 patients (60 patients in each group) every 3 weeks 
      until 6 months. The primary endpoints were to assess the change in cognitive 
      score from baseline in both the treatment group. The result of the present study 
      showed that the patients treated with DNP and NART agonist have similar efficacy 
      and safety profile. Considering the clinical benefit, improvement in sign and 
      symptoms of was numerically greater in DNP-treated patients as compared to NART 
      agonist. However, a statistical difference in terms of clinical benefit was 
      similar between both the treatment groups. Overall, both the study drugs were 
      found comparable in relieving the symptoms of AD. This indicates that NART is a 
      potential target for the treatment of AD in China. The results of the present 
      study may help to design a large clinical trial to evaluate the efficacy and 
      safety of NART agonist in comparison with DNP in AD patients.
FAU - Wang, Jianhong
AU  - Wang J
AD  - Department of Neurology, Sichuan Provincial People's Hospital, University of 
      Electronic Science and Technology of China, Chengdu, China.
FAU - Yang, Shu
AU  - Yang S
AD  - Department of Neurology, Sichuan Provincial People's Hospital, University of 
      Electronic Science and Technology of China, Chengdu, China.
FAU - Hu, Zicheng
AU  - Hu Z
AD  - Department of Neurology, Daping Hospital, Third Military Medical University, 
      Chongqing, China.
FAU - Yang, Haimei
AU  - Yang H
AD  - Department of Neurology, Daping Hospital, Third Military Medical University, 
      Chongqing, China.
FAU - Wei, Dong
AU  - Wei D
AD  - Department of Neurology, The People's Hospital of Lezhi, Ziyang, Sichuan, China.
FAU - Wang, Duozi
AU  - Wang D
AD  - Department of Neurology, Sichuan Provincial People's Hospital, University of 
      Electronic Science and Technology of China, Chengdu, China.
FAU - Guo, Fuqiang
AU  - Guo F
AD  - Department of Neurology, Sichuan Provincial People's Hospital, University of 
      Electronic Science and Technology of China, Chengdu, China.
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - Pakistan
TA  - Pak J Pharm Sci
JT  - Pakistan journal of pharmaceutical sciences
JID - 9426356
RN  - 0 (Amyloid beta-Peptides)
RN  - 0 (Cholinesterase Inhibitors)
RN  - 0 (Enzyme Inhibitors)
RN  - 0 (Indoles)
RN  - 0 (Maleimides)
RN  - 8SSC91326P (Donepezil)
RN  - L79H6N0V6C (bisindolylmaleimide I)
SB  - IM
MH  - Aged
MH  - Amyloid beta-Peptides
MH  - China
MH  - Cholinesterase Inhibitors/*therapeutic use
MH  - Donepezil/*therapeutic use
MH  - Enzyme Inhibitors/*therapeutic use
MH  - Female
MH  - Humans
MH  - Indoles/*therapeutic use
MH  - Male
MH  - Maleimides/*therapeutic use
EDAT- 2020/01/03 06:00
MHDA- 2020/07/02 06:00
CRDT- 2020/01/03 06:00
PHST- 2020/01/03 06:00 [entrez]
PHST- 2020/01/03 06:00 [pubmed]
PHST- 2020/07/02 06:00 [medline]
PST - ppublish
SO  - Pak J Pharm Sci. 2019 Sep;32(5(Special)):2427-2432.